Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and ...

Learn about B-Cell Acute Lymphoblastic Leukemia (B-ALL), its symptoms, diagnosis, causes, and treatment options. Understand ...

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric ...

Highlights in acute lymphoblastic leukemia (ALL), presented at the American Society of Hematology (ASH) 2024 Annual Meeting and Exposition, include studies on pediatric and adult disease ...

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

The work is published in the journal Biomarker Research. B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common ...

Exploring variables associated with prolonged survival in AML with TP53 aberration.

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

Imagine helping save a child’s life — just by buying a ticket to win a brand-new home. That’s the idea behind the st. Jude ...